Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19
Onco-hematologic patients are highly susceptible to SARS-CoV-2 infection and, once infected, frequently develop COVID-19 due to the immunosuppression caused by tumor growth, chemotherapy and immunosuppressive therapy. In addition, COVID-19 has also been recognized as a further cause of HBV reactivat...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/11/5/567 |
| _version_ | 1827667423212339200 |
|---|---|
| author | Caterina Sagnelli Antonello Sica Massimiliano Creta Alessandra Borsetti Massimo Ciccozzi Evangelista Sagnelli |
| author_facet | Caterina Sagnelli Antonello Sica Massimiliano Creta Alessandra Borsetti Massimo Ciccozzi Evangelista Sagnelli |
| author_sort | Caterina Sagnelli |
| collection | DOAJ |
| description | Onco-hematologic patients are highly susceptible to SARS-CoV-2 infection and, once infected, frequently develop COVID-19 due to the immunosuppression caused by tumor growth, chemotherapy and immunosuppressive therapy. In addition, COVID-19 has also been recognized as a further cause of HBV reactivation, since its treatment includes the administration of corticosteroids and some immunosuppressive drugs. Consequently, onco-hematologic patients should undergo SARS-CoV-2 vaccination and comply with the rules imposed by lockdowns or other forms of social distancing. Furthermore, onco-hematologic facilities should be adapted to new needs and provided with numerically adequate health personnel vaccinated against SARS-CoV-2 infection. Onco-hematologic patients, both HBsAg-positive and HBsAg-negative/HBcAb-positive, may develop HBV reactivation, made possible by the support of the covalently closed circular DNA (cccDNA) persisting in the hepatocytic nuclei of patients with an ongoing or past HBV infection. This occurrence must be prevented by administering high genetic barrier HBV nucleo(t)side analogues before and throughout the antineoplastic treatment, and then during a long-term post-treatment follow up. The prevention of HBV reactivation during the SARS-CoV-2 pandemic is the topic of this narrative review. |
| first_indexed | 2024-03-10T03:11:26Z |
| format | Article |
| id | doaj.art-672c05e9ab3e43159823810183bd865b |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T03:11:26Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-672c05e9ab3e43159823810183bd865b2023-11-23T12:32:42ZengMDPI AGPathogens2076-08172022-05-0111556710.3390/pathogens11050567Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19Caterina Sagnelli0Antonello Sica1Massimiliano Creta2Alessandra Borsetti3Massimo Ciccozzi4Evangelista Sagnelli5Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania “Luigi Vanvitelli”, 80131 Naples, ItalyDepartment of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80131 Naples, ItalyDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, ItalyNational HIV/AIDS Research Center, Istituto Superiore di Sanità, 00161 Rome, ItalyMedical Statistics and Molecular Epidemiology Unit, Campus Bio-Medico University, 00128 Rome, ItalyDepartment of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania “Luigi Vanvitelli”, 80131 Naples, ItalyOnco-hematologic patients are highly susceptible to SARS-CoV-2 infection and, once infected, frequently develop COVID-19 due to the immunosuppression caused by tumor growth, chemotherapy and immunosuppressive therapy. In addition, COVID-19 has also been recognized as a further cause of HBV reactivation, since its treatment includes the administration of corticosteroids and some immunosuppressive drugs. Consequently, onco-hematologic patients should undergo SARS-CoV-2 vaccination and comply with the rules imposed by lockdowns or other forms of social distancing. Furthermore, onco-hematologic facilities should be adapted to new needs and provided with numerically adequate health personnel vaccinated against SARS-CoV-2 infection. Onco-hematologic patients, both HBsAg-positive and HBsAg-negative/HBcAb-positive, may develop HBV reactivation, made possible by the support of the covalently closed circular DNA (cccDNA) persisting in the hepatocytic nuclei of patients with an ongoing or past HBV infection. This occurrence must be prevented by administering high genetic barrier HBV nucleo(t)side analogues before and throughout the antineoplastic treatment, and then during a long-term post-treatment follow up. The prevention of HBV reactivation during the SARS-CoV-2 pandemic is the topic of this narrative review.https://www.mdpi.com/2076-0817/11/5/567COVID-19SARS-CoV-2hepatitis B virusreactivationchemotherapyimmunosuppression |
| spellingShingle | Caterina Sagnelli Antonello Sica Massimiliano Creta Alessandra Borsetti Massimo Ciccozzi Evangelista Sagnelli Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19 Pathogens COVID-19 SARS-CoV-2 hepatitis B virus reactivation chemotherapy immunosuppression |
| title | Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19 |
| title_full | Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19 |
| title_fullStr | Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19 |
| title_full_unstemmed | Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19 |
| title_short | Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19 |
| title_sort | prevention of hbv reactivation in hemato oncologic setting during covid 19 |
| topic | COVID-19 SARS-CoV-2 hepatitis B virus reactivation chemotherapy immunosuppression |
| url | https://www.mdpi.com/2076-0817/11/5/567 |
| work_keys_str_mv | AT caterinasagnelli preventionofhbvreactivationinhematooncologicsettingduringcovid19 AT antonellosica preventionofhbvreactivationinhematooncologicsettingduringcovid19 AT massimilianocreta preventionofhbvreactivationinhematooncologicsettingduringcovid19 AT alessandraborsetti preventionofhbvreactivationinhematooncologicsettingduringcovid19 AT massimociccozzi preventionofhbvreactivationinhematooncologicsettingduringcovid19 AT evangelistasagnelli preventionofhbvreactivationinhematooncologicsettingduringcovid19 |